Literature DB >> 2078489

Phase II trial with Brequinar (DUP-785, NSC 368390) in patients with metastatic colorectal cancer: a study of the Early Clinical Trials Group of the EORTC.

P F Dodion1, T Wagener, G Stoter, A Drozd, L M Lev, T Skovsgaard, J Renard, F Cavalli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2078489     DOI： 10.1093/oxfordjournals.annonc.a057680

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  11 in total

1.  The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors.

Authors:  Christine R Cuthbertson; Hui Guo; Armita Kyani; Joseph T Madak; Zahra Arabzada; Nouri Neamati
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-23

2.  Identification of Human Dihydroorotate Dehydrogenase Inhibitor by a Pharmacophore-Based Virtual Screening Study.

Authors:  Salvatore Galati; Stefano Sainas; Marta Giorgis; Donatella Boschi; Marco L Lolli; Gabriella Ortore; Giulio Poli; Tiziano Tuccinardi
Journal:  Molecules       Date:  2022-06-07       Impact factor: 4.927

3.  Catalytic enzyme histochemistry and biochemical analysis of dihydroorotate dehydrogenase/oxidase and succinate dehydrogenase in mammalian tissues, cells and mitochondria.

Authors:  M Löffler; C Becker; E Wegerle; G Schuster
Journal:  Histochem Cell Biol       Date:  1996-02       Impact factor: 4.304

4.  Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.

Authors:  H A Burris; E Raymond; A Awada; J G Kuhn; T J O'Rourke; J Brentzel; W Lynch; S Y King; T D Brown; D D Von Hoff
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

5.  Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH).

Authors:  Marianne Lucas-Hourani; Hélène Munier-Lehmann; Farah El Mazouni; Nicholas A Malmquist; Jane Harpon; Eloi P Coutant; Sandrine Guillou; Olivier Helynck; Anne Noel; Artur Scherf; Margaret A Phillips; Frédéric Tangy; Pierre-Olivier Vidalain; Yves L Janin
Journal:  J Med Chem       Date:  2015-06-30       Impact factor: 7.446

Review 6.  Oncology Therapeutics Targeting the Metabolism of Amino Acids.

Authors:  Nefertiti Muhammad; Hyun Min Lee; Jiyeon Kim
Journal:  Cells       Date:  2020-08-15       Impact factor: 6.600

Review 7.  Re-Discovery of Pyrimidine Salvage as Target in Cancer Therapy.

Authors:  Melanie Walter; Patrick Herr
Journal:  Cells       Date:  2022-02-20       Impact factor: 6.600

8.  Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma.

Authors:  Yajie Yu; Jane Ding; Shunqin Zhu; Ahmet Alptekin; Zheng Dong; Chunhong Yan; Yunhong Zha; Han-Fei Ding
Journal:  Cell Death Dis       Date:  2021-08-30       Impact factor: 8.469

9.  Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase.

Authors:  Joseph T Madak; Christine R Cuthbertson; Yoshinari Miyata; Shuzo Tamura; Elyse M Petrunak; Jeanne A Stuckey; Yanyan Han; Miao He; Duxin Sun; Hollis D Showalter; Nouri Neamati
Journal:  J Med Chem       Date:  2018-05-14       Impact factor: 7.446

Review 10.  RNA modifications in hematopoietic malignancies: a new research frontier.

Authors:  Ying Qing; Rui Su; Jianjun Chen
Journal:  Blood       Date:  2021-08-26       Impact factor: 25.476
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.